Posts

FDA Approves Novo Nordisk's Awiqli: First Once-Weekly Basal Insulin for Type 2 Diabetes

on
The FDA approved Awiqli (insulin icodec-abae) injection 700 units/mL on March 26, 2026, as the first and only once-weekly basal insulin for adults with type 2 diabetes to improve glycemic control alongside diet and exercise. Awiqli reduces basal insulin injections from seven daily to one weekly, administered via Awiqli FlexTouch on the same day each week. Approval based on ONWARDS phase 3a program: four trials with ~2,680 adults showing A1C reductions comparable to daily basal insulins and a consistent safety profile. Awiqli addresses challenges of daily injections, offering personalized care for type 2 diabetes patients. Not approved for children or adolescents; common side effects include hypoglycemia, injection site reactions, and weight gain. Sources:

Recordati Confirms Non-Binding €10.9 Billion Full Takeover Offer from CVC Capital Partners

on

"We need to put some bad ideas to bed": Inside Incubate's battles for biotech on Capitol Hill

on

Novartis Agrees to Acquire Excellergy for Up to $2 Billion to Bolster Allergy Portfolio with Potential Xolair Successor

on

FDA Approves Rocket Pharma's Kresladi Gene Therapy for Ultra-Rare LAD-I After Setbacks

on

Beam's Base Editor Advances to Pivotal Development on Back of Impressive AATD Data

on

Pinnacle Medicines Secures $89M Series B Funding for Oral Peptide Pipeline

on

Kodiak Sciences' Zenkuda Succeeds in Second Phase 3 Trial for Diabetic Retinopathy

on

First Patient Dosed in Phase 1b/2 Trial of HLX701 Combination Therapy for Advanced Colorectal Cancer

on

Novo Nordisk's GLP-1 Pipeline Advances with Oral Innovations Amid Analyst Concerns on Oral Trends

on

Artera Appoints Damon Lanphear as New CTO and Promotes Nicole Ossey to SVP of People

on

FDA Clears Philips' EchoNavigator R5.0 with DeviceGuide for Real-Time AI Guidance in Minimally Invasive Mitral Valve Repair

on

Swift Medical's Swift Ray Receives FDA 510(k) Clearance for Advanced Wound Imaging

on